{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:14:59Z","timestamp":1786976099557,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd001909.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000}}],"reference-count":93,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001909.pub4","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T13:25:30Z","timestamp":1702301130000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Lamotrigine add-on therapy for drug-resistant focal epilepsy"],"prefix":"10.1002","volume":"2023","author":[{"given":"Mariangela","family":"Panebianco","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics; Institute of Systems, Molecular and Integrative Biology, University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bresnahan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics; Institute of Systems, Molecular and Integrative Biology, University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony G","family":"Marson","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics; Institute of Systems, Molecular and Integrative Biology, University of Liverpool; Liverpool UK"},{"name":"The Walton Centre NHS Foundation Trust; Liverpool UK"},{"name":"Liverpool Health Partners; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"key":"10.1002\/14651858.CD001909.pub4-BIB0001|cit1","doi-asserted-by":"crossref","unstructured":"Baulac M Leon T O'Brien TJ Whalen E Barrett J A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures Epilepsy Research 2010 91 1 10 9","DOI":"10.1016\/j.eplepsyres.2010.05.008"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0920-1211(89)90007-7","article-title":"Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy","volume":"4","author":"Binnie","year":"1989","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0404.1996.tb07060.x","article-title":"Controlled trial of lamotrigine (Lamictal) for treatment-resistant partial seizures","volume":"94","author":"Boas","year":"1996","journal-title":"Acta Neurologica Scandinavica"},{"issue":"8","key":"10.1002\/14651858.CD001909.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1212\/WNL.53.8.1724","article-title":"A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children","volume":"53","author":"Duchowny","year":"1999","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD001909.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1528-1157.1989.tb05309.x","article-title":"Controlled trial of lamotrigine (lamictal) for refractory partial seizures","volume":"30","author":"Jawad","year":"1989","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0920-1211(90)90099-H","article-title":"A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures","volume":"7","author":"Loiseau","year":"1990","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1212\/WNL.43.11.2284","article-title":"Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. US Lamotrigine Protocol 0.5 Clinical Trial Group","volume":"43","author":"Matsuo","year":"1993","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD001909.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1528-1157.1994.tb02920.x","article-title":"Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial","volume":"35","author":"Messenheimer","year":"1994","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1212\/01.wnl.0000277698.33743.8b","article-title":"Lamotrigine extended-release as adjunctive therapy for partial seizures","volume":"69","author":"Naritoku","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1212\/01.wnl.0000285493.08622.35","article-title":"Adjunctive lamotrigine for partial seizures in patients aged 1 to 24 months","volume":"70","author":"Pi\u00f1a-Garza","year":"2008","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0896-6974(95)00034-B","article-title":"Lamotrigine: a six-month, placebo-controlled, safety and tolerance study","volume":"8","author":"Schachter","year":"1995","journal-title":"Journal of Epilepsy"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jnnp.56.5.448","article-title":"Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures","volume":"56","author":"Schapel","year":"1993","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001909.pub4-BIB0013|cit13","first-page":"66","article-title":"Add-on treatment with lamotrigine for intractable partial epilepsy: a placebo-controlled, cross-over trial","volume":"34","author":"Schmidt","year":"1993","journal-title":"Epilepsia"},{"issue":"2","key":"10.1002\/14651858.CD001909.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1528-1157.1993.tb02417.x","article-title":"Outcomes of add-on treatment with lamotrigine in partial epilepsy","volume":"34","author":"Smith","year":"1993","journal-title":"Epilepsia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001909.pub4-BIB0015|cit15","first-page":"321, Abstract n","article-title":"Equivalence among generic AEDs (equigen)-single-dose study","volume":"15","author":"Berg","year":"2015","journal-title":"Epilepsy Currents"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0016|cit16","doi-asserted-by":"crossref","unstructured":"Berg M Welty TE Gidal BE Diaz FJ Krebill R Szaflarski JP Bioequivalence between generic and branded lamotrigine in people with epilepsy: the EQUIGEN randomized clinical trial JAMA Neurology 2017 74 8 919 26 10.1001\/jamaneurol.2017.0497 28654954","DOI":"10.1001\/jamaneurol.2017.0497"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Biton V Di Memmo J Shukla R Lee YY Poverennova I Demchenko V Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study Epilepsy & Behavior 2010 19 3 352 8","DOI":"10.1016\/j.yebeh.2010.07.022"},{"issue":"5","key":"10.1002\/14651858.CD001909.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40261-013-0070-4","article-title":"Long-term tolerability and safety of lamotrigine extended-release: pooled analysis of three clinical trials","volume":"33","author":"Biton","year":"2013","journal-title":"Clinical Drug Investigation"},{"issue":"6","key":"10.1002\/14651858.CD001909.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2710.2012.01351.x","article-title":"Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics","volume":"37","author":"Brzakovic","year":"2012","journal-title":"Journal of Clinical Pharmacy & Therapeutics"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001909.pub4-BIB0020|cit20","first-page":"135","article-title":"Controlled trial of lamotrigine for the treatment of refractory partial seizures","volume":"45","author":"Carignani","year":"2004","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001909.pub4-BIB0021|cit21","first-page":"124","article-title":"Controlled trial of lamotrigine for the treatment of refractory partial seizures","volume":"47","author":"Carignani","year":"2006","journal-title":"Epilepsia"},{"issue":"1","key":"10.1002\/14651858.CD001909.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.4081\/ni.2009.e6","article-title":"Cognitive effects of lamotrigine versus topiramate as adjunctive therapy in older adults with epilepsy","volume":"1","author":"Chung","year":"2009","journal-title":"Neurology International"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.eplepsyres.2016.02.012","article-title":"Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimes","volume":"122","author":"Contin","year":"2016","journal-title":"Epilepsy Research"},{"issue":"2","key":"10.1002\/14651858.CD001909.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/ane.12086","article-title":"Indirect comparison of clobazam and other therapies for Lennox-Gastaut Syndrome","volume":"128","author":"Cramer","year":"2013","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"107815","DOI":"10.1016\/j.yebeh.2021.107815","article-title":"Anti-seizure medications and efficacy against focal to bilateral tonic-clonic seizures: a systematic review with relevance for SUDEP prevention","volume":"117","author":"Cutillo","year":"2021","journal-title":"Epilepsy & Behavior"},{"issue":"1-2","key":"10.1002\/14651858.CD001909.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.eplepsyres.2012.03.015","article-title":"Analysis of three lamotrigine extended-release clinical trials: comparison of pragmatic ITT and LOCF methodologies","volume":"101","author":"French","year":"2012","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0027|cit27","first-page":"e144","article-title":"The EpiNet-first trials now recruiting patients with newly diagnosed epilepsy","volume":"357","author":"Frith","year":"2015","journal-title":"Journal of the Neurological Sciences"},{"issue":"1","key":"10.1002\/14651858.CD001909.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1590\/S1984-82502012000100011","article-title":"Interchangeability among therapeutic equivalents of lamotrigine: evaluation of quality of life","volume":"48","author":"Girolineto","year":"2012","journal-title":"Brazilian Journal of Pharmaceutical Sciences"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD001909.pub4-BIB0029|cit29","first-page":"100","article-title":"Pragmatic intent-to-treat analysis for lamotrigine extended release adjunctive therapy in patients with intractable partial seizures","volume":"49","author":"Hammer","year":"2008","journal-title":"Epilepsia"},{"issue":"8","key":"10.1002\/14651858.CD001909.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/11634260-000000000-00000","article-title":"Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study","volume":"26","author":"Hartung","year":"2012","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1002\/14651858.CD001909.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.yebeh.2012.11.052","article-title":"The longer-term cognitive effects of adjunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting","volume":"26","author":"Helmstaedter","year":"2013","journal-title":"Epilepsy & Behaviour"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0032|cit32","unstructured":"Comparing efficacy and tolerability of lamotrigine and levetiracetam in elderly patient with diagnosed epilepsy en.irct.ir\/trial\/11767"},{"issue":"4","key":"10.1002\/14651858.CD001909.pub4-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"807","DOI":"10.21037\/tp-20-379","article-title":"Efficacy and tolerability of lamotrigine in the treatment of focal epilepsy among children and adolescents: a meta-analysis","volume":"10","author":"Ji","year":"2021","journal-title":"Translational Pediatrics"},{"issue":"17","key":"10.1002\/14651858.CD001909.pub4-BIB0034|cit34","first-page":"1174","article-title":"Efficacy and safety of the combined therapy of valproic acid and lamotrigine for epileptics","volume":"92","author":"Kang","year":"2012","journal-title":"Zhonghua yi xue za zhi"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.seizure.2017.12.008","article-title":"Unblinded, randomized multicenter trial comparing lamotrigine and valproate combination with controlled-release carbamazepine monotherapy as initial drug regimen in untreated epilepsy","volume":"55","author":"Lee","year":"2018","journal-title":"Seizure"},{"issue":"10282","key":"10.1002\/14651858.CD001909.pub4-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(21)00247-6","article-title":"The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"issue":"75","key":"10.1002\/14651858.CD001909.pub4-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta25750","article-title":"Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs","volume":"25","author":"Marson","year":"2021","journal-title":"Health Technology Assessment"},{"issue":"10","key":"10.1002\/14651858.CD001909.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/epi.14554","article-title":"Impact of carbamazepine, lamotrigine, and levetiracetam on vascular risk markers and lipid-lowering agents in the elderly","volume":"59","author":"Mintzer","year":"2018","journal-title":"Epilepsia"},{"issue":"Suppl6","key":"10.1002\/14651858.CD001909.pub4-BIB0039|cit39","first-page":"369","article-title":"An analysis of the efficacy of lamotrigine extended-release adjunctive therapy in subjects with partial epilepsy by number of concomitant AEDs","volume":"48","author":"Montouris","year":"2007","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0040|cit40","unstructured":"Second-line treatment choice for epilepsy clinicaltrials.gov\/study\/NCT00208520"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0041|cit41","unstructured":"A study for evaluating the efficacy and safety of Zonisamide and Lamotrigine (Lamictal) for subjects with refractory simple partial, complex partial or partial with secondary generalized seizures clinicaltrials.gov\/study\/NCT00292461"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0042|cit42","unstructured":"The efficacy and safety of low dose combination of LTG and VPA compared to CBZ monotherapy clinicaltrials.gov\/study\/NCT00807989"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0043|cit43","unstructured":"Cognitive AED outcomes in pediatric localization related epilepsy (COPE) clinicaltrials.gov\/study\/NCT01891890"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0044|cit44","unstructured":"Valproate dose reduction and its clinical evaluation by introducing Lamotrigine in Japanese women with epilepsy - single arm, multicenter, and open-label study clinicaltrials.gov\/study\/NCT02100644"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0045|cit45","unstructured":"A trial of generic substitution of antiepileptic drugs clinicaltrials.gov\/show\/NCT02429596"},{"issue":"4","key":"10.1002\/14651858.CD001909.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3805\/jjes.25.425","article-title":"Single-blind and controlled comparative study of lamotrigine with zonisamide for refractory pediatric epilepsy","volume":"25","author":"Ohtahara","year":"2008","journal-title":"Journal of the Japan Epilepsy Society"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3389\/fnins.2017.00585","article-title":"The effect of lamotrigine and levetiracetam on TMS-evoked EEG responses depends on stimulation intensity","volume":"11","author":"Premoli","year":"2017","journal-title":"Frontiers in Neuroscience"},{"issue":"4","key":"10.1002\/14651858.CD001909.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S1474-4422(16)00014-4","article-title":"Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial","volume":"15","year":"2016","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0920-1211(90)90077-9","article-title":"A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy","volume":"6","author":"Sander","year":"1990","journal-title":"Epilepsy Research"},{"issue":"2","key":"10.1002\/14651858.CD001909.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1684\/epd.2014.0650","article-title":"Early add-on treatment vs alternative monotherapy in patients with partial epilepsy","volume":"16","author":"Semah","year":"2014","journal-title":"Epileptic Disorders"},{"issue":"3","key":"10.1002\/14651858.CD001909.pub4-BIB0051|cit51","first-page":"359","article-title":"Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine","volume":"50","author":"Sethi","year":"2002","journal-title":"Neurology India"},{"issue":"13","key":"10.1002\/14651858.CD001909.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1212\/WNL.0000000000001971","article-title":"Long-term outcomes of generalized tonic-clonic seizures in a childhood absence epilepsy trial","volume":"85","author":"Shinnar","year":"2015","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/jnnp.57.8.921","article-title":"Vigabatrin and lamotrigine in refractory epilepsy","volume":"57","author":"Stolarek","year":"1994","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"23","key":"10.1002\/14651858.CD001909.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22230","article-title":"Antiepileptic drug monitoring in pregnancy (EMPiRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies","volume":"22","author":"Thangaratinam","year":"2018","journal-title":"Health Technology Assessment (Winchester, England)"},{"issue":"9","key":"10.1002\/14651858.CD001909.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/epi.13095","article-title":"Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: a field test of the FDA bioequivalence standard","volume":"56","author":"Ting","year":"2015","journal-title":"Epilepsia"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD001909.pub4-BIB0056|cit56","first-page":"118","article-title":"Evaluation of sudden unexpected death in epilepsy (SUDEP) occurring in lamotrigine (LTG) clinical trials","volume":"53","author":"Tomson","year":"2012","journal-title":"Epilepsia"},{"issue":"1","key":"10.1002\/14651858.CD001909.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1528-1167.2012.03689.x","article-title":"Sudden unexpected death in epilepsy in lamotrigine randomized-controlled trials","volume":"54","author":"Tomson","year":"2013","journal-title":"Epilepsia"},{"issue":"Suppl Florence","key":"10.1002\/14651858.CD001909.pub4-BIB0058|cit58","first-page":"97","article-title":"Use of lamotrigine as adjunctive therapy in patients with mental retardation and epilepsy; an interim analysis of a double blind study with evaluation of behavioural effects","volume":"41","author":"Veendrick-Meekes","year":"2000","journal-title":"Epilepsia"},{"issue":"7","key":"10.1002\/14651858.CD001909.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/epi.14450","article-title":"The effects of oxcarbazepine, levetiracetam, and lamotrigine on semen quality, sexual function, and sex hormones in male adults with epilepsy","volume":"59","author":"Wu","year":"2018","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD001909.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1248\/bpb.35.487","article-title":"Influence of concomitant antiepileptic drugs on plasma lamotrigine concentration in adult Japanese epilepsy patients","volume":"35","author":"Yamamoto","year":"2012","journal-title":"Biological & Pharmaceutical Bulletin"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0061|cit61","unstructured":"Low vs. standard daily doses of antiepileptic drugs in newly diagnosed, previously untreated epilepsy (STANDLOW) clinicaltrials.gov\/study\/NCT03689114"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0062|cit62","first-page":"230","article-title":"Neuropsychological assessment in lamotrigine treated epileptic patients","volume":"28","author":"Banks","year":"1991","journal-title":"Clinical and Experimental Neurology"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/978-94-017-8914-1_24","article-title":"What are the arguments for and against rational therapy for epilepsy?","volume":"813","author":"Barker-Haliski","year":"2014","journal-title":"Advances in Experimental Medicine & Biology"},{"issue":"7","key":"10.1002\/14651858.CD001909.pub4-BIB0064|cit64","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007783.pub3","article-title":"Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures","author":"Bresnahan","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0140-6736(95)91208-8","article-title":"Remission of epilepsy: results from the national general practice study of epilepsy","volume":"346","author":"Cockerell","year":"1995","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD001909.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Proposal for revised classification of epilepsies and epileptic syndromes","volume":"30","author":"Commission on Classification and Terminology of the International League Against Epilepsy","year":"1989","journal-title":"Epilepsia"},{"issue":"6","key":"10.1002\/14651858.CD001909.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1055\/s-0040-1718719","article-title":"Epilepsy-Definition, Classification, Pathophysiology, and Epidemiology","volume":"40","author":"Falco-Walter","year":"2020","journal-title":"Seminars in Neurology"},{"issue":"4","key":"10.1002\/14651858.CD001909.pub4-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.0013-9580.2005.66104.x","article-title":"Epileptic seizures and epilepsy: definitions proposed by the International League A Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)","volume":"46","author":"Fisher","year":"2005","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0069|cit69","unstructured":"GRADEpro McMaster University 2014"},{"issue":"3","key":"10.1002\/14651858.CD001909.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/npr2.12196","article-title":"Neuropharmacology of antiseizure drugs","volume":"41","author":"Hakami","year":"2021","journal-title":"Neuropsychopharmacology Reports"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0071|cit71","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"c365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD001909.pub4-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x.","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0074|cit74","volume-title":"Mechanisms of Action in Antiepileptic Drugs","author":"Leach","year":"1995"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0075|cit75","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6. Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6"},{"issue":"3","key":"10.1002\/14651858.CD001909.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0165-6147(00)01974-X","article-title":"Current status and future directions in the pharmacotherapy of epilepsy","volume":"23","author":"Loscher","year":"2002","journal-title":"Trends in Pharmacological Sciences"},{"issue":"11","key":"10.1002\/14651858.CD001909.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1517\/14656566.2014.922544","article-title":"Pharmacotherapy of focal epilepsy","volume":"15","author":"Lyer","year":"2014","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"8","key":"10.1002\/14651858.CD001909.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1517\/14656566.2012.665875","article-title":"Lamotrigine use in pregnancy","volume":"13","author":"Moore","year":"2012","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD001909.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1517\/14728214.2013.750294","article-title":"Emerging drugs for focal epilepsy","volume":"18","author":"Mula","year":"2013","journal-title":"Expert Opinion on Emerging Drugs"},{"issue":"4","key":"10.1002\/14651858.CD001909.pub4-BIB0080|cit80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002896.pub2","article-title":"Vagus nerve stimulation for partial seizures","author":"Panebianco","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD001909.pub4-BIB0081|cit81","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001415.pub3","article-title":"Gabapentin add-on treatment for drug-resistant focal epilepsy","author":"Panebianco","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD001909.pub4-BIB0082|cit82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001415.pub4","article-title":"Gabapentin add-on treatment for drug-resistant focal epilepsy","author":"Panebianco","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD001909.pub4-BIB0083|cit83","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002896.pub3","article-title":"Vagus nerve stimulation for focal seizures","author":"Panebianco","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD001909.pub4-BIB0084|cit84","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005612.pub5","article-title":"Pregabalin add-on for drug-resistant focal epilepsy","author":"Panebianco","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0085|cit85","unstructured":"Perucca E French JA Balestrin S Braga P Galanopoulou AS Jain S Which terms should be used to describe medications used in the treatment of epilepsy? An ILAE position paper Epilepsia 2022"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0086|cit86","unstructured":"Review Manager (RevMan) The Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"4","key":"10.1002\/14651858.CD001909.pub4-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001909.pub4-BIB0088|cit88","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions V ersion 6.4 (updated August 2023). Cochrane, 2023 Available from: training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD001909.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jocn.2012.05.024","article-title":"Lamotrigine in epilepsy, pregnancy and psychiatry - a drug for all seasons?","volume":"20","author":"Vajda","year":"2013","journal-title":"Journal of Clinical Neuroscience"},{"issue":"6","key":"10.1002\/14651858.CD001909.pub4-BIB0090|cit90","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010541.pub3","article-title":"Surgery for epilepsy","author":"West","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD001909.pub4-BIB0091|cit91","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001909.pub3","article-title":"Lamotrigine add-on therapy for drug-resistant focal epilepsy","author":"Panebianco","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD001909.pub4-BIB0092|cit92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001909","article-title":"Lamotrigine add-on for drug-resistant partial epilepsy","author":"Ramaratnam","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD001909.pub4-BIB0093|cit93","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001909.pub2","article-title":"Lamotrigine add-on for drug-resistant partial epilepsy","author":"Ramaratnam","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:33:45Z","timestamp":1757417625000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001909.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":93,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001909.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,11]]}}}